Phase II trial of fludarabine induction followed by CAMPATH-1H [alemtuzumab] consolidation in untreated patients with B-cell chronic lymphocytic leukemia.

Trial Profile

Phase II trial of fludarabine induction followed by CAMPATH-1H [alemtuzumab] consolidation in untreated patients with B-cell chronic lymphocytic leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Alemtuzumab (Primary) ; Fludarabine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jun 2015 Status changed from active, no longer recruiting to completed as per Clinicaltrials.gov.
    • 01 Apr 2011 Planned End Date changed to 1 Mar 2012, according to Clinicaltrials.gov.
    • 01 Apr 2011 Status changed from completed to active, no longer recruiting, according to Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top